Differential contribution of renal cytochrome P450 enzymes to kidney endothelial dysfunction and vascular oxidative stress in obesity

Biochem Pharmacol. 2022 Jan:195:114850. doi: 10.1016/j.bcp.2021.114850. Epub 2021 Nov 22.

Abstract

Arachidonic acid (AA)-derived cytochrome P450 (CYP) derivatives, epoxyeicosatrienoic acids (EETs) and 20-hidroxyeicosatetranoic acid (20-HETE), play a key role in kidney tubular and vascular functions and blood pressure. Altered metabolism of CYP epoxygenases and CYP hydroxylases has differentially been involved in the pathogenesis of metabolic disease-associated vascular complications, although the mechanisms responsible for the vascular injury are unclear. The present study aimed to assess whether obesity-induced changes in CYP enzymes may contribute to oxidative stress and endothelial dysfunction in kidney preglomerular arteries. Endothelial function and reactive oxygen species (ROS) production were assessed in interlobar arteries of obese Zucker rats (OZR) and their lean counterparts lean Zucker rats (LZR) and the effects of CYP2C and CYP4A inhibitors sulfaphenazole and HET0016, respectively, were examined on the endothelium-dependent relaxations and O2- and H2O2 levels of preglomerular arteries. Non-nitric oxide (NO) non-prostanoid endothelium-derived hyperpolarization (EDH)-type responses were preserved but resistant to the CYP epoxygenase blocker sulfaphenazole in OZR in contrast to those in LZR. Sulfaphenazole did not further inhibit reduced arterial H2O2 levels, and CYP2C11/CYP2C23 enzymes were downregulated in intrarenal arteries from OZR. Renal EDH-mediated relaxations were preserved in obese rats by the enhanced activity and expression of endothelial calcium-activated potassium channels (KCa). CYP4A blockade restored impaired NO-mediated dilatation and inhibited augmented O2- production in kidney arteries from OZR. The current data demonstrate that both decreased endothelial CYP2C11/ CYP2C23-derived vasodilator H2O2 and augmented CYP4A-derived 20-HETE contribute to endothelial dysfunction and vascular oxidative stress in obesity. CYP4A inhibitors ameliorate arterial oxidative stress and restore endothelial function which suggests its therapeutic potential for the vascular complications of obesity-associated kidney injury.

Keywords: CYP2C epoxygenases; CYP4 hydroxylase; Endothelial dysfunction; Kidney preglomerular arteries; Obesity; Reactive oxygen species.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amidines / pharmacology
  • Animals
  • Aryl Hydrocarbon Hydroxylases / metabolism
  • Cytochrome P-450 CYP2J2 / metabolism
  • Cytochrome P-450 CYP4A / metabolism
  • Cytochrome P-450 Enzyme System / metabolism*
  • Cytochrome P450 Family 2 / metabolism
  • Endothelium, Vascular / metabolism*
  • Hydrogen Peroxide / metabolism
  • Hydroxyeicosatetraenoic Acids / antagonists & inhibitors
  • Hydroxyeicosatetraenoic Acids / metabolism
  • Kidney / blood supply
  • Kidney / metabolism*
  • Male
  • Obesity / metabolism*
  • Obesity / physiopathology
  • Oxidative Stress*
  • Rats
  • Rats, Zucker
  • Reactive Oxygen Species / metabolism
  • Renal Artery / drug effects
  • Renal Artery / metabolism*
  • Renal Artery / physiopathology
  • Steroid 16-alpha-Hydroxylase / metabolism
  • Sulfaphenazole / pharmacology
  • Vasodilation / drug effects

Substances

  • Amidines
  • Cyp2c23 protein, rat
  • HET0016
  • Hydroxyeicosatetraenoic Acids
  • Reactive Oxygen Species
  • Sulfaphenazole
  • 20-hydroxy-5,8,11,14-eicosatetraenoic acid
  • Cytochrome P-450 Enzyme System
  • Hydrogen Peroxide
  • Aryl Hydrocarbon Hydroxylases
  • CYP2C11 protein, rat
  • Cytochrome P-450 CYP2J2
  • Cytochrome P450 Family 2
  • Steroid 16-alpha-Hydroxylase
  • Cytochrome P-450 CYP4A